Veeva Systems Inc.
VEEV · Healthcare
$279.23
Caricamento grafico…
Notizie
Ultime notizie su questo titolo
VEEV Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate Fast
Veeva Systems raised its fiscal 2027 revenue guidance to $3.682-$3.687B (implying ~15% growth), driven by strong Vault CRM adoption with commitments from 12 of top 20 biopharma firms and 180+ live customers. The company's Falcon AI product has five early adopters, though execution remains a key near-term priority. While profitability is maintained with a 44% operating margin, newer initiatives like CRM migrations and AI monetization still require sustained execution.
The Market Just Told You Which Layer Of AI Biology It Is Paying For
Recent earnings in life sciences technology reveal that the market is rewarding companies with proprietary data and systems of record over those selling software or AI models alone. Veeva Systems beat expectations with strong AI product adoption, while Certara missed on modest software growth and Recursion Pharmaceuticals fell short on revenue expectations. MindWalk Holdings, which owns curated biological data infrastructure, is positioned to benefit from this trend with its HYFT Technology and newly launched ReefIQ platform, though it remains unprofitable with modest recurring revenue.
Here's How Much You'd Have If You Invested $1000 in Veeva Systems a Decade Ago
A $1,000 investment in Veeva Systems (VEEV) made in September 2016 would be worth $6,890.53 as of September 3, 2026, representing a 589.05% gain. This significantly outperformed the S&P 500's 251.68% return over the same period. Veeva continues to benefit from strong demand for life sciences cloud platforms, with fiscal 2026 revenues reaching $3.19 billion, up 16% year-over-year.
Veeva's Exiting President Sold $2.8 Million in Stock: What Investors Need to Know
Thomas D. Schwenger, President and Chief Customer Officer of Veeva Systems, sold 10,000 shares worth $2.8 million on August 27, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sale should not alarm investors as Schwenger is departing the company on October 2, 2026, and the transaction was pre-planned for liquidity purposes rather than a market timing bet. Veeva has rebounded strongly with a 55% gain over six months following successful earnings beats and a successful transition to its own Vault CRM platform.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
RSPH, an equal-weight healthcare ETF launched in 2006, has gained 17.92% year-to-date and 29.15% over the past year as of August 31, 2026. With $826.52 million in assets and a 0.40% expense ratio, it offers diversified exposure to 63 healthcare holdings. However, cheaper alternatives like VHT (0.09% expense ratio) and XLV (0.08% expense ratio) may be more suitable for cost-conscious investors seeking lower-risk options.